COLLABORATION AGREEMENT BY AND BETWEEN PDL BIOPHARMA, INC. AND BRISTOL-MYERS SQUIBB COMPANY AUGUST 18, 2008Collaboration Agreement • November 7th, 2008 • PDL Biopharma, Inc. • Biological products, (no disgnostic substances)
THIS COLLABORATION AGREEMENT (the “Agreement”) is made and entered into as of August 18, 2008 (the “Execution Date”) by and between PDL Biopharma, Inc., a Delaware corporation having its principal place of business at 1400 Seaport Blvd., Redwood City, CA 94063 (“PDL”) and Bristol-Myers Squibb Company, a Delaware corporation headquartered at 345 Park Avenue, New York, New York 10154 (“BMS”), effective as of the Effective Date (as defined in Section 12.6), except for Article 10 and Section 12.6, which shall be effective as of the Execution Date. PDL and BMS are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASEConfidential Separation Agreement and General Release • November 7th, 2008 • PDL Biopharma, Inc. • Biological products, (no disgnostic substances) • California
This Confidential Separation Agreement and General Release (this “Agreement”) is made and entered into by and between Richard Murray, an individual (“Dr. Murray”), and PDL BioPharma, Inc., a Delaware corporation (the “Company”), and is effective as of the Effective Date set forth below.
